Oncology and Neuroscience Blog from Elekta

The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO’s 52nd Annual Meeting (October 31 – November 4) at the San Diego Convention Center.

NSCLC, the most common form of lung cancer, arises from a number of causes, including active smoking, passive smoking (secondhand smoke), asbestos and radon exposure. Lung cancer is the leading cause of cancer death in men and women. Each year, primary carcinoma of the lungs affects 93,000 men and 80,000 women in the United States and 86 percent die within five years of diagnosis. The incidence of lung cancer peaks between the ages 55 and 65.

“The research in which our Lung Cancer Consortium is engaged is completely consistent with ASTRO’s theme this year: Gathering Evidence; Proving Value,” says Joel Goldwein, M.D., Senior Vice President and Director of Medical Affairs for Elekta. “The researchers have made a number of very important discoveries, some of which I believe will be likely to change how SBRT is administered to this challenging group of patients. It doesn’t get much more valuable than that.”

Click here to read more about the papers, their authors and Elekta’s advanced SBRT technology: http://www.elekta.com/healthcare_international_press_release_20071063.php